MedTrace Logo

Teriflunomide Male Transmission Study

NCT02679885 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-01-02

No results posted yet for this study

Summary

It is known that teriflunomide, a treatment for relapsing forms of multiple sclerosis, can be found in low concentrations in semen. Because the drug has been associated with teratogenicity in laboratory animals, the question is raised as to whether the drug can be detected in female partners of sexually active males who are taking the drug to treat their multiple sclerosis.

Conditions

Sponsors & Collaborators

  • Griffin Hospital

    lead OTHER

Principal Investigators

  • Joseph Guarnaccia, MD · MSTC

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-08-31
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02679885 on ClinicalTrials.gov